Clinuvel Pharmaceuticals Ltd. (CUVL) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Clinuvel Pharmaceuticals Ltd. (CUVL) operates in the Healthcare sector, specifically the Medical - Pharmaceuticals industry, with a market capitalization near $310.6M, listed on NASDAQ, carrying a beta of 0.57 to the broader market. Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Led by Philippe Jacques Wolgen, public since 2026-07-13.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for CUVL as of 2026-08-31; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.